# US 2012/0083761 A1 · Methods for selective eradication of metastasizing cancer cells ex vivo using multidomain biotags

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083761 A1
- Document ID: US20120083761A1
- Status: Published application
- Kind: A1
- Application number: 13/168,951
- Filed: 2011-06-25
- Published: 2012-04-05
- Earliest claimed: 2010-06-25
- Inventors: MAREK MALECKI; Raf Malecki
- Web page: https://patentgrep.com/patent/US20120083761A1

## CPC

- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K 49/0058: {Antibodies}
- A61K 49/0065: {the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle}
- A61K 49/1875: {coated or functionalised with an antibody}
- G01N 33/56966: {Animal cells}
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for treating cancer in a subject is provided, the method comprising administering to the subject an effective dose of a multidomain biotag that targets one or more cancer cells; establishing a vascular access in the subject; connecting the vascular access to a tube to establish an extracorporeal circulation of a bodily fluid; and exposing the extracorporeal circulation to one or more doses of radiation, killing biotag-targeted cancer cells.

## Claims

### Claim 1

A method for treating cancer in a subject, the method comprising:
administering to the subject an effective dose of a multidomain biotag that targets one or more cancer cells;
establishing a vascular access in the subject;
connecting the vascular access to an anti-coagulation coated tube to establish an extracorporeal circulation of a bodily fluid; and
exposing the extracorporeal circulation to one or more doses of radiation, killing biotag-targeted cancer cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biotag comprises
one or more binding domains;
one or more internalization domain;
one or more endosomal escape domain;
one or more lysosomal escape domain; and
one or more metal-binding domain (MBD);
and a metal nanoparticle tag, wherein the metal nanoparticle tag is chelated to the MBD.

### Claim 3 (depends on 1)

The method of claim 1, further comprising administering an effective dose of a cancer cell specific ROS blocker.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cancer-cell specific anti-ROS blocker is part of the multidomain biotag.

### Claim 5 (depends on 2)

The method of claim 2, wherein at least one of the one or more target binding domains is a cancer biomarker binding domain.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cancer biomarker is ErbB 1-4, TfR or a mutant thereof.

### Claim 7 (depends on 2)

The method of claim 2, wherein at least one of the one or more target binding domains is a cancer cell specific anti-ROS blocker.

### Claim 8 (depends on 3)

The method of claim 3, wherein the molecular probe has at least two target binding domains, the at least two target binding domains comprising a cancer biomarker binding domain and a cancer cell specific anti-ROS blocker.

### Claim 9 (depends on 2)

The method of claim 2, wherein the metal nanoparticle tag is a noble metal.

### Claim 10 (depends on 9)

The method of claim 9, wherein the noble metal is Au, Pd, Pt, Ag.

### Claim 11 (depends on 2)

The method of claim 2, wherein the metal nanoparticle tag is a superparamagnetic metal.

### Claim 12 (depends on 11)

The method of claim 11, wherein the superparamagnetic metal is Gd, Eu, Tb, Fe, Ni, Co, Ru, Cu, F or a stable or radioactive isotopes or products of decay.

### Claim 13 (depends on 2)

The method of claim 2, wherein the metal nanoparticle tag is a core-shell nanoparticle, the core shell nanoparticle comprising an inner superparamagnetic metal core and an outer noble metal shell.

### Claim 14 (depends on 2)

The method of claim 2, wherein the one or more binding domain is an scFv, sdFv, CDR, or SDR.

### Claim 15 (depends on 14)

The method of claim 14, wherein the scFv, sdFv, CDR, or SDR.is an anti-ErbB 1-1, an anti-TfR scFv, sdFv, CDR, or SDR or a mutant thereof.

### Claim 16 (depends on 1)

The method of claim 1, wherein the one or more cancer cells are metastasizing, circulating, dormant, and/or metastatic cancer cells.

### Claim 17 (depends on 1)

The method of claim 1, wherein the one of more cancer cells are primary hematological neoplasm cells.

### Claim 18 (depends on 1)

The method of claim 1, wherein the bodily fluid of the extracorporeal circulation is selected from the group consisting of blood, lymph and cerebrospinal fluid.

### Claim 19 (depends on 1)

The method of claim 1, wherein the one or more rounds of radiation is X-ray radiation.

### Claim 20 (depends on 1)

The method of claim 1, wherein the one or more rounds of radiation is AC electromagnetic radiation.
